What is a stock summary page? Click here for an overview.
Business Description
Vaccinex Inc
NAICS : 325412
SIC : 2834
ISIN : US9186401033
Description
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 44.28 | |||||
| Equity-to-Asset | -0.96 | |||||
| Debt-to-Equity | -0.01 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -217.73 | |||||
| Beneish M-Score | -7.75 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -64.8 | |||||
| 3-Year EBITDA Growth Rate | 61.6 | |||||
| 3-Year EPS without NRI Growth Rate | 62.6 | |||||
| 3-Year FCF Growth Rate | 65.3 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 72.32 | |||||
| 9-Day RSI | 61.17 | |||||
| 14-Day RSI | 55.86 | |||||
| 3-1 Month Momentum % | -52.99 | |||||
| 6-1 Month Momentum % | -83.73 | |||||
| 12-1 Month Momentum % | -90.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.5 | |||||
| Quick Ratio | 0.5 | |||||
| Cash Ratio | 0.22 | |||||
| Days Sales Outstanding | 802.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -163.1 | |||||
| Shareholder Yield % | -339.37 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -3117.3 | |||||
| Net Margin % | -3100.5 | |||||
| FCF Margin % | -2693.18 | |||||
| ROA % | -447.61 | |||||
| ROIC % | -2165.4 | |||||
| 3-Year ROIIC % | -666.96 | |||||
| ROC (Joel Greenblatt) % | -11302.55 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.88 | |||||
| EV-to-EBIT | -0.15 | |||||
| EV-to-EBITDA | -0.15 | |||||
| EV-to-Revenue | 4.68 | |||||
| EV-to-FCF | -0.16 | |||||
| Price-to-GF-Value | 0.11 | |||||
| Earnings Yield (Greenblatt) % | -666.67 | |||||
| FCF Yield % | -671.62 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:VCNX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vaccinex Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.601 | ||
| EPS (TTM) ($) | -10.131 | ||
| Beta | 1.47 | ||
| 3-Year Sharpe Ratio | -1.81 | ||
| 3-Year Sortino Ratio | -1.76 | ||
| Volatility % | 104.42 | ||
| 14-Day RSI | 55.86 | ||
| 14-Day ATR ($) | 0.221539 | ||
| 20-Day SMA ($) | 0.760496 | ||
| 12-1 Month Momentum % | -90.73 | ||
| 52-Week Range ($) | 0.2521 - 8.9 | ||
| Shares Outstanding (Mil) | 2.68 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vaccinex Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vaccinex Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Vaccinex Inc Frequently Asked Questions
What is Vaccinex Inc(VCNX)'s stock price today?
The current price of VCNX is $0.90. The 52 week high of VCNX is $8.90 and 52 week low is $0.25.
When is next earnings date of Vaccinex Inc(VCNX)?
The next earnings date of Vaccinex Inc(VCNX) is 2025-05-15 Est..
Does Vaccinex Inc(VCNX) pay dividends? If so, how much?
Vaccinex Inc(VCNX) does not pay dividend.
Guru Commentaries on OTCPK:VCNX
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers